Swedish monitoring systems developer Senzime has started a clinical study of its CliniSenz System for monitoring the lactate levels in patients who have undergone surgery for esophageal cancer.

CliniSenz System is a combination of the firm’s CliniSenz Analyser and OnZurf Probe.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

CliniSenz Analyser allows remote patient monitoring, needs a small volume of samples for analysis and can be used for early identification of complications and diagnosis.

Compatible with microdialysis catheters such as OnZurf Probe, the analyser features an enzyme-based heat flow detection incorporated on a microfluidic chip, which aids in avoiding substance interferences.

Designed for continuous sampling and collection of biomarkers, Onzurf Probe comes with an attachment site, which enables placement on the surface of an organ without penetration or pressure.

The microdialysis sampler can be used with analytical systems such as Clinisenz Analyser and high-performance liquid chromatography (HPLC).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Senzime CEO Lena Söderström said: “The clinical market is looking for systems that allow continuous monitoring of biomarkers in blood and tissues to rapidly detect post-operative complications and to guide timely interventions.

“The early detection is expected to allow faster intervention and prevention of complications after the surgery.”

“Effective monitoring systems are necessary in order to reduce the number of painful and care-intensive complications after surgery.”

Being conducted at the Uppsala University Hospital, the trial will use the system to assess the local lactate levels in esophageal cancer patients after surgery, for early identification of signs of leakage before detection by standard diagnostics.

It is reported that initial assessments from the trial are expected to be revealed after enrolling 20 patients.

The early detection is expected to allow faster intervention and prevention of complications after the surgery.


Image: CliniSenz Analyzer. Photo: courtesy of Senzime.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact